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ABSTRACT
Several studies have compared the results of unrelated donor bone marrow transplantation (UBMT) and
unrelated donor cord blood transplantation (UCBT). To objectively analyze these data, we performed a
systematic review and meta-analysis of pooled data on comparative studies of UCBT and UBMT in patients
requiring hematopoietic stem cell transplantation. Combining the studies, 161 children and 316 adults
undergoing UCBT (mostly 1 or 2 antigen-mismatched), along with 316 children and 996 adults undergoing
UBMT (almost entirely fully matched with the recipient), were analyzed. T-cell–depleted UBMT was ex-
cluded; where data were available, only fully matched UBMT was used in the analysis. Pooled comparisons of
studies of UCBT and UBMT in children found that the incidence of chronic graft-versus-host disease (GVHD)
was lower with UCBT (relative risk [RR]  0.26; 95% confidence interval [CI]  0.12–0.57; P  .16), but the
incidence of grade III–IV acute GVHD did not differ (RR  1.46; 95% CI  0.42–5.03; P  .55). There was
no difference in 2-year OS in children when studies were pooled (RR  0.76; 95% CI  0.31–1.87; P  .55).
For adults, transplantation-related mortality (pooled estimate, 1.04; 95% CI  0.52–2.08; P  .91) and
disease-free survival (DFS) (pooled estimate, 0.59; 95% CI  0.18–1.96; P  .39) were not statistically
different. Because of the unavailability of randomized controlled trials, pooled analysis of nonrandomized
comparative studies was performed. Thus, our meta-analysis confirmed that UCBT in children and adults had
consistently equivalent survival outcomes compared with UBMT despite greater donor–recipient HLA dis-
parity with UCBT.
© 2007 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Bone marrow transplantation (BMT) and pe-
ipheral blood stem cell transplantation (PBSCT)
rom HLA-matched donors have been successfully
sed to treat many malignant and nonmalignant
isorders [1]. Cord blood transplantation (CBT) has
radually emerged as an alternative mode of hema-
opoietic stem cell transplantation (HSCT) [2].
ince the ﬁrst sibling CBT in 1989 [3] and the ﬁrst t
44nrelated donor CBT (UCBT) in 1993 [4], there
as been a rapid increase in the use of this treatment
odality for patients lacking a suitably matched
one marrow donor. The numbers increased from a
ew hundred UBCTs in the 1990s to approximately
000 by the year 2002 [5], followed by an exponen-
ial rise to more than 7000 UCBTs performed to
ate. This increased use of UCBT has been fueled
n large part by reports of excellent outcomes with
his modality emerging from a number of studies
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Unrelated Donor Umbilical Cord Blood versus Bone Marrow Transplantation 445irectly comparing the outcomes of unrelated donor
MT (UBMT) and UCBT.
In UBMT, a donor fully matched at all 6 HLA-A,
B, and -DRB1 alleles is often required. However,
ecause of the vast polymorphism of HLA alleles, not
ll patients will be able to ﬁnd a matched donor, either
ibling or unrelated [6,7]; the likelihood of this is even
ower for patients of non Caucasian ethnic groups
8,9]. However, the hematopoietic robustness [10,11]
nd immunologic naivety [12] of cord blood (CB) cells
llows us to select CB with up to 1 to 2 antigen
ismatches out of the standard 6 alleles. This immu-
ologic permissiveness of CB has dramatically in-
reased the likelihood of ﬁnding a suitable donor for
SCT [13].
Despite increased HLA disparity using CB, com-
arable results have been obtained between UCBT
nd UBMT in terms of probabilities of engraftment,
raft-versus-host disease (GVHD), and survival. This
s likely because the excessive mortality secondary to
elayed engraftment and graft failure compared with
BMT is balanced by lower mortality from other
auses, including GVHD [14]. Immune recovery has
lso been shown to be prompt and comparable to that
n UBMT [15]. Several major comparative studies of
CBT versus UBMT have reported some similarities
s well as differences. The main objective of this sys-
ematic review was to evaluate whether UCBT is
quivalent to UBMT in treating adults and children
ith malignant and nonmalignant disorders.
ETHODS
To aid in making treatment decisions for patients
eeding allogeneic HSCT, we systematically reviewed
ll data on comparative studies of UCBT versus
BMT in which survival was the key outcome mea-
ure. To obtain reliable evidence on the relative effect
f UCBT versus UBMT in the primary treatment of
dults and children with malignant and nonmalignant
isorders, results from independent and comparable
tudies were integrated to increase statistical power.
he primary outcome of interest for our analysis was
urvival; secondary outcomes studied included en-
raftment, GVHD, transplantation-related mortality
TRM), and relapse.
earch Strategy
Following established guidelines, we performed a
iterature search using OVID. The databases searched
ere Medline (1966–January 28, 2006), The Co-
hrane Central Register of Controlled Trials (Co-
hrane Library, Issue 1, 2006), Cochrane Database of
ystematic Reviews, ACP Journal Club, and Database
f Abstracts of Reviews of Effect. EMBASE (197–
anuary 28, 2006) was searched using Dialog Datastar. the search terms used were “cord blood,” “bone mar-
ow,” and the alternate search terms “transplant,”
transplantation,” and “transplants.” Whereas the ini-
ial search limited publications to randomized con-
rolled trials, this did not yield any useful search re-
ults, and consequently we expanded our search
riteria to include all listed clinical trials. To further
nhance our search, we included all journal articles
nd limited the search terms to the title. Abstracts of
apers presented at the American Society of Hema-
ology, International Bone Marrow Transplant Reg-
stry, American Society of Blood and Marrow Trans-
lantation, and European Society of Bone Marrow
ransplant Meetings published before January 2006
ere also hand-searched, checking for “cord blood,”
bone marrow,” and “transplant” in the indexes. Full
ext papers were obtained to extract the data for this
nalysis. References of retrieved articles were also
hecked for any relevant trials.
election Criteria
All comparative studies of UCBT versus UBMT
ere selected. Patients were children and adults re-
uiring allogeneic HSCT to treat malignant and non-
alignant disorders (principally leukemia). Data for
eutrophil and platelet engraftment, TRM, relapse,
VHD, and overall or event-free survival had to be
vailable either on paper or through personal com-
unication. Each study was critically appraised for
alidity based on consistency, accuracy, and balance
etween treatment groups. Three independent re-
iewers independently extracted data from each study
nto standardized data extraction forms and reviewed
he identiﬁed studies from the aforementioned
ources for the eligibility criteria speciﬁed earlier.
tudies without comparable patient demographics be-
ween the 2 comparative groups were excluded.
here a study in abstract form was updated (in, eg,
he form of a full paper), the latest version was used.
here were far more review papers than primary stud-
es on cord blood transplantation, and all review pa-
ers reiterating previous data were excluded. The re-
ults of assessment by independent reviewers were
ompared, and any apparent disagreement was re-
erred to the responsible statistician so that errors and
missions could be rectiﬁed whenever possible.
tatistical Analysis
To estimate the treatment effects, outcomes were
alculated as either relative risks (RR) or hazard ratios
HR), with their respective 95% conﬁdence intervals
CIs). HRs were the preferred form of data for calcu-
ating overall mortality, disease-free survival (DFS),
RM, and relapse occurring over time. When HRs
ere not given in a paper, data were extracted from
he respective Kaplan-Meier curves to estimate HRs.
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W. H. Y. Khee et al.446he pooled effect estimates were calculated using the
eview Manager 4.2.8 statistical package. The I2 sta-
istic was used to assess statistical heterogeneity, with
2  50% considered to indicate signiﬁcant result
eterogeneity. When signiﬁcant result heterogeneity
as found with the ﬁxed-effects model, a random-
ffects model was used to estimate the overall treat-
ent effect.
ESULTS
utcome of Search
From the MEDLINE and PubMed database as of
ugust 20, 2006, there were 1124 initial hits using
cord blood,” “bone marrow,” and “transplant,”
transplants,” or “transplantation” as search terms,
hich included 2 randomized controlled trials and 35
linical trials. The listed randomized controlled trials
ere inappropriate for our analysis; 1 was a compari-
on of conditioning regimens [16], whereas the other
as a broad summary of a symposium [17]. Of the 35
tudies, only 2 ﬁt our criteria for selection—that they
e comparisons of clinical outcomes between BMT
nd CBT in either children or adults including long-
erm survival as part of the analysis. To expand our
earch, we included all journal articles, limiting the
earch terms to the title, and found 49 studies, 6 of
hich ﬁt the aforementioned criteria for selection. A
apanese study [18] that analyzed only patients with
cute leukemia and that had some overlap with later
apers was excluded. Also excluded were a pediatric
aper that studied only patients with “bone marrow
ailure syndromes” [19] and a study from China that
as a retrospective analysis of only patients with acute
ymphoblastic leukemia [20]. A study that analyzed
nly hematopoietic reconstitution, but not overall
utcomes, was excluded [21], as was an interesting
aper that analyzed only patients requiring mechani-Figure 1. Selection of stual ventilation [22]. A paper by Schonberger et al. [23]
as excluded because 1/2 of the BMTs and 1/3 of the
BTs were from related donors.
The signiﬁcant huts that we found in the OVID
atabase (CENTRAL, CDSR, ACP, DARE) had al-
eady appeared in our Medline search. We searched
bstracts of conference proceedings/meetings of the
merican Society of Hematology (ASH) and Euro-
ean Bone Marrow Transplant (EBMT) between
995 and January 2006. We found 6 suitable abstracts,
hich were overlaps or superseded by subsequent full-
ext papers. We found no suitable clinical trials in our
earch of databases of ongoing trials (http://www.
ontrolled-trials.com; http://clinicaltrials.gov/ct/gui;
nd http://www.trialscentral.org/index). Finally, we
hose 6 studies for our analysis, 3 in adults and 3 in
hildren (Figure 1). Table 1 presents a summary of
tudy design, patient characteristics, and treatment of
ach of these studies.
haracteristics of Included Studies
As shown in Table 1, 3 studies were in pediatric
atients (Rocha et al. [24], Dalle et al. [25], Barker
t al. [26]) and 3 studies were in adults (Takahashi et
l. [27], Laughlin et al. [28], and Rocha et al. [29]).
he studies in children involved a total of 161 patients
eceiving UCBT and 316 patients receiving UBMT.
lthough fewer adults had CB samples with adequate
ell counts, there were more adults with hematologic
iseases necessitating HSCT. Consequently, there
ere more adults, with a combined total of 316 adults
ndergoing UCBT and 996 undergoing UBMT in
he comparative studies. In 2 of the adult studies
28,29] and 2 of the pediatric studies [25,26], compar-
sons were made between only full-matched UBMT
6/6 match) and 0–2 antigen-mismatched UBCTs.
he pediatric study of Rocha et al. [24] included
BMT, which were 6/6 matched (80.5%), 5/6dies for analysis.
Table 1. Characteristics of Included Studies
Author
Center/Study
Group Study Population
Study
Arm
Number of
Patients Disease Status
Median Age
(Range),
Years
Male: Female
Ratio HLA Matching
Rocha et al.24 Eurocord Acute leukemia/
children
UCBT 99 Poor risk: 32%
Good risk: 68%
6 (2.5-10) 1.41 8% 6/6 HLA-matched
43% 1 antigen-mismatched
41% 2 antigen-mismatched
8% > 3 antigen-mismatched
UBMT 262 Poor risk: 39%
Good risk: 61%
8 (5-12) 1.54 80.5% 6/6 HLA-matched
17.6% 1 antigen-mismatched
0.4% 2 antigen-mismatched
Barker et al.26 Minneapolis Haematologic
diseases/children
UCBT 26 High risk: 58%
Standard risk: 42%
4.5 (0.2-17.9) Not available 19% 6/6 HLA-matched
46% 1 antigen-mismatched
31% 2 antigen-mismatched
4% 3 antigen-mismatched
UBMT 26 High risk: 58%
Standard risk: 42%
4.6 (0.6-17.7) Not available 100% 6/6 HLA-matched
Dalle et al.25 Hopital Sainte-
Justine,
Canada
Hematologic
diseases/
children
UCBT 36 Hematologic malignancies: 83%
(high risk: 16%, standard risk: 67%)
Nonmalignancies: 17%
7.5 (0.1-19.5) 1.40 6% 6/6 HLA-matched
50% 1 antigen-mismatched
44% 2 antigen-mismatched
UBMT 28 Hematologic malignancies: 71%
(high risk: 7%, standard risk: 64%)
Nonmalignancies: 29%
6.8 (0.4-21.2) 2.11 100% 6/6 HLA-matched
Rocha et al.29 Eurocord Acute leukemia/
adults
UCBT 98 Poor risk: 48%
Good risk: 52%
24.5 (15-55) 1.04 6% 6/6 HLA-matched
51% 1 antigen-mismatched
39% 2 antigen-mismatched
4% 3 antigen-mismatched
UBMT 584 Poor risk: 33%
Good risk: 67%
32 (15-59) 1.17 100% 6/6 HLA-matched
Takahashi et al.27 Institute of
Medical
Science,
Tokyo
Haematological
malignancy/
adults
UCBT 68 Poor risk: 60%
Good risk: 40%
36 (16-53) 1.63 0% 6/6 HLA-matched
21% 1 antigen-mismatched
54% 2 antigen-mismatched
25% > 3 antigen-mismatched
UBMT 45 Poor risk: 57%
Good risk: 43%
26 (16–50) 2.03 87% 6/6 HLA-matched
13% 1 antigen-mismatched
Laughlin et al.28 IBMTR/NYBC Hematologic
malignancy/
adults
UCBT 150 CR1, CP1 or RA: 20%
> CR2, CP2 or AP: 32%
Relapse, PIF, BP, or RAEBT: 43%
Missing: 5%
16-30: 52%
31-50: 41%
51-60: 7%
1.70 0% 6/6 HLA-matched
23% 1 antigen-mismatched
77% 2 antigen-mismatched
UBMT 367 CR1, CP1, or RA: 40%
> CR2, CP2, or AP: 31%
Relapse, PIF, BP, or RAEBT: 29%
16-30: 52%
31-50: 41%
51-60: 7%
1.25 100% 6/6 HLA-matched
Risk deﬁnitions are adapted from different deﬁnitions used in the papers. Standard risk  patients with no malignancy or malignancy in ﬁrst or second complete remission (CR1 or CR2), chronic phase
CML, or no high-risk cytogenetics (eg, acute lymphoblastic leukemia with t(4;11) or t(9;22)). High risk patients in malignancy in third complete remission (CR3), relapse, chronic myeloid leukemia
(CML) beyond chronic phase, or who had myelodysplasia or high-risk cytogenetics. Poor risk  patients with malignancy in CR3 or beyond or CML in accelerated or blast phase (AP or BP). Good
risk  Patients with malignancy in CR1 or CR2 or CML in chronic phase.
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W. H. Y. Khee et al.448atched (17.6%), and 4/6 matched (0.4%). Because
he data for the patients with 6/6 matches were not
nalyzed separately, the data extracted for meta-anal-
sis included some mismatched UBMTs from that
tudy. The study of Laughlin et al. [28] analyzed the
dults with mismatched UBMT separately, and we
ncluded only the patients with matched UBMT in
ur analysis of that study. In all other instances, we
sed only fully matched UBMT in our analysis. We
xcluded from our analysis patients receiving T-cell–
epleted UBMT in the studies by Rocha et al. [24] and
arker et al. [26].
alidity of Included Studies
Complete randomization was not possible in ei-
her the pediatric or adult studies. In view of long-
tanding data on the use of unrelated BM to treat
atients with hematologic malignancies, all patients
ad at least a search initiated for a fully matched
nrelated BM donor either before or concomitant
ith the search for CB blood. When this was not
vailable, when transplantation was urgent, or when
he transplant physician preferred to search for a CB
nit directly, a 0–2 antigen-mismatched unrelated CB
onor was searched for. In all of the studies, the
atients had minor differences in terms of age, sex,
nd disease type and stage, but the differences be-
ween UCBT and UBMT usually were not signiﬁcant
Table 1). Because the procurement and availability of
B and BM units differ greatly, blinding of the studies
as not possible.
ndpoints Measured
The chosen studies all explored the endpoints of
verall survival (OS) and recurrence-free survival/
Review: Umbilical cord transplant for haematological diseas
Comparison: Umbilical cord blood transplantation (UCBT) Vs Ma
Outcome: Early transplant related mortality in children (day 1
HydutS
or subcategory log[HR] (SE) 9
Barker 2001         0.7100 (0.3100)
Rocha 2001          0.7560 (0.2930)
Total (95% CI)
Test for heterogeneity: Chi² = 0.01, df = 1 (P = 0.91), I² = 0%
Test for overall effect: Z = 3.45 (P = 0.0006)
0.001 0.01 0.1
Favours UCFigure 2. Early TRMFS. All of the studies also explored white cell and
latelet engraftment, GVHD, and TRM.
hildren
In the studies on children, white cell count recov-
ry was not very comparable between the studies.
oth studies (Barker et al. [26] and Rocha et al. [24])
howed a lower probability of white cell engraftment
or UCBT, at 45 days (HR  0.92; 95% CI  0.79–
.08) and at 60 days (HR  0.84; 95% CI  0.76–
.93), respectively, although the difference was not
tatistically signiﬁcant in Barker’s study. Time to
latelet independence or engraftment in children was
imilar in both UCBT and UBMT when the Barker
t al. [26] and Rocha et al. [24] studies were pooled
HR  1.06; 95% CI  0.97–1.15; P  .19).
As shown in Figure 2, the risk of having early (day
00) TRM in children was evaluated in 2 studies by
ocha et al. [24] and Barker et al. [26], and the pooled
stimate favored UBMT (HR  2.08; 95% CI 
.37–3.16; P  .0006). Only the Rocha et al. [24]
tudy provided HRs for the risk of relapse and showed
signiﬁcantly lower relapse rate in patients with
CBT (HR  1.96; 95% CI  1.12–3.43). There
ere no signiﬁcant differences in OS at 2 years when
he Barker et al. [26] and Rocha et al. [24] studies were
ooled (HR  0.76; 95% CI  0.31–1.87; P  .55).
S at 3 years in the Dalle et al. study [25] also revealed
o signiﬁcant differences (HR  1.95; 95% CI 
.44–2.54; P  .91). Only the Rocha et al. [24] study
rovided HRs for the data on DFS (Figure 3).
Combining the studies by Barker et al. [26], Rocha
t al. [24], and Dalle et al. [25], there was no signiﬁ-
ant difference in the incidence of acute GVHD grade
I–IV (HR 0.96; 95% CI 0.44–2.09; P .92) and
unrelated donors (UBMT)           
  
)dexif( RHthgieW)d
% 95% CI
47.18 2.03 [1.11, 3.73]        
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Unrelated Donor Umbilical Cord Blood versus Bone Marrow Transplantation 449rade III–IV (HR  1.46; 95% CI  0.42–5.03; P 
55) between UCBT and UBMT (Figure 4). However,
here was considerable result heterogeneity between
he studies in this measure (I2  50%). Pooling the
arker et al. [26] and Rocha et al. [24] studies with
egard to chronic GVHD (Figure 4) indicated that the
isk of this complication is signiﬁcantly lower in pa-
ients with UCBT (HR  0.26; 95% CI  0.12–0.57;
 .0007).
Review: Umbilical cord transplant for haematological diseases
Comparison: Umbilical cord blood transplantation (UCBT) Vs Matched u
Outcome: Survival in children                                            
ydutS
)ES( ]RH[golyrogetacbus ro
01 Disease free survival
Rocha 2001          -0.5100 (0.1500)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.40 (P = 0.0007)
02 Overall survival at 2 years
Barker 2001         0.4600 (0.6800)
Rocha 2001          -0.5600 (0.0900)
Subtotal (95% CI)
Test for heterogeneity: Chi² = 2.21, df = 1 (P = 0.14), I² = 54.8%
Test for overall effect: Z = 0.59 (P = 0.55)
03 Overall survival at 3 years
Dalle 2004          0.0500 (0.4500)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
0.001 0.01 0
Favours U
Figure 3. Su
Review: Umbilical cord transplant for haematological diseases
Comparison: 01 Umbilical cord blood transplantation (UCBT) Vs Matched unrelated 
Outcome: 11 GVHD in children                                             
TMBUTBCUydutS
N/nN/nyrogetacbus ro
01 Grade (II-IV)
Barker 2001         11/26               9/26        
Rocha 2001          33/99             148/262       
Dalle 2004          5/36               1/28        
Subtotal (95% CI) 161                316
Total events: 49 (UCBT), 158 (UBMT)
Test for heterogeneity: Chi² = 6.31, df = 2 (P = 0.04), I² = 68.3%
Test for overall effect: Z = 0.10 (P = 0.92)
02 Grade (III-IV)
Barker 2001         5/26               2/26        
Rocha 2001          21/99              77/262       
Dalle 2004          4/36               0/28        
Subtotal (95% CI) 161                316
Total events: 30 (UCBT), 79 (UBMT)
Test for heterogeneity: Chi² = 4.60, df = 2 (P = 0.10), I² = 56.5%
Test for overall effect: Z = 0.60 (P = 0.55)
03 Chronic GVHD
Barker 2001         1/26               5/26        
Rocha 2001          5/43              86/201       
Subtotal (95% CI) 69                 227
Total events: 6 (UCBT), 91 (UBMT)
Test for heterogeneity: Chi² = 0.07, df = 1 (P = 0.79), I² = 0%
Test for overall effect: Z = 3.39 (P = 0.0007)
0.1Figure 4. GVHDdults
The pooled estimate from the trials on adult pa-
ients showed that the risks of experiencing a relapse
HR  0.86; 95% CI  0.62–1.19; P  .36) and early
RM (HR  1.04; 95% CI  0.52–2.08; P  .91)
ere the same in UCBT and UBMT recipients (Fig-
res 5 and 6). Although measures of OS could not be
ooled because of different deﬁnitions used, 3 studies
donors (UBMT)                             
)modnar( RHthgieW)mod
IC %59%IC
100.00 0.60 [0.45, 0.81]        
100.00 0.60 [0.45, 0.81]
3.98 1.58 [0.42, 6.01]        
96.02 0.57 [0.48, 0.68]        
100.00 0.76 [0.31, 1.87]
100.00 1.05 [0.44, 2.54]        
100.00 1.05 [0.44, 2.54]
10 100 1000
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100.00 0.96 [0.44, 2.09]
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W. H. Y. Khee et al.450ad adequate data on DFS in adults (Figure 7). The
verall treatment effect shows that DFS was similar in
oth groups (HR  1.56; 95% CI  0.76–3.17; P 
23). However Takahashi et al. [27] reported a statis-
ically signiﬁcant difference (HR 4.48, 95% CI 2.44–
.23) in favor of UCBT (Figure 7). We believe that
he difference cannot be completely explained by the
egree of HLA matching of the UCBT and UBMT
ecipients. As shown in Table 1, in Laughlin et al.
28], most of the CB was 4/6 antigen matched, and our
nalysis comparison was made only with BM that was
/6 antigen-matched. For the adult study of Rocha et
l. [29], almost equal numbers of CB were 4/6 and 5/6
ntigen-matched, whereas BM was all at least 6/6
ntigen-matched. However, in the Japanese study,
ost of the CB was 4/6 antigen-matched, with some
/6 or 3/6 matched; 87% of the BM was 6/6 antigen-
atched, and 13% was 5/6 matched. The excellent
esults of UCBT in the Japanese study cannot be
xplained by patient weight or nucleated cell counts of
he CB unit.
White cell engraftment in adults was consistently
uperior with UBMT, although the studies could not
e pooled, because this was measured at day 42 by
akahashi et al. [27] (HR  0.90; 95% CI  0.82–
.99; P  .03) and day 100 in the Laughlin et al. [28]
HR 0.76; 95%CI 0.69–0.84; P .00001). Platelet
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ured on day 120 in Takahashi et al. [27] (HR  0.89;
5% CI  0.77–1.02; P  .10) and at 1 year in
aughlin et al. [28] (HR  0.50; 95% CI  0.40–
.62; P  .00001), so these results also could not be
ooled. Acute GVHD was seen less often in UCBT,
ut the studies by Takahashi et al. [27] (HR  0.45;
5% CI  0.31–0.66; P  .05) and Rocha et al. [29]
HR  0.69; 95% CI  0.46–1.04; P  .01) could not
e pooled, because Takahashi et al. [27] evaluated this
nly in patients surviving 21 days or longer after
ransplantation with evidence of engraftment. Never-
heless, both studies clearly showed that UCBT was
igniﬁcantly associated with less acute GVHD.
ISCUSSION
In this meta-analysis of UCBT versus UBMT,
CBT was associated with slower engraftment, less
VHD, a similar relapse rate, and equivalent survival.
e applied a systematic methodology in which the
tudies were searched, selected, and analyzed, but be-
ause allocation to a particular treatment group was
ased on the availability of suitable unrelated BM or
B donors, blinded or randomized controlled trials
ere not available. To randomize patients in a study
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Unrelated Donor Umbilical Cord Blood versus Bone Marrow Transplantation 451omparing unrelated UCBT and UBMT, each patient
ould need an unrelated CB and BM donor available
t the point of randomization. Conducting such a
tudy has not been possible to date. As such, nonran-
omized comparative studies were selected for this
eta-analysis. The baseline characteristics of patients
ere comparable in these studies; therefore, the stud-
es were pooled to estimate the overall treatment ef-
ect. Because these were all retrospective studies, an
ntention-to-treat analysis was impossible. Although it
s true that patient characteristics were similar for
oth UBMT and UCBT and that the lack of avail-
bility of fully matched unrelated donors often pred-
cated the need for less well-matched CB grafts, we
annot fully exclude the possibility of center biases in
reatment and selection of patients for UBMT or
CBT. Some studies had no absolute numbers for
ata, and HRs could not be derived for some studies.
here were, however, explicit statements of intent, as
vident in the studies of Barker et al. [26], Takahashi
t al. [27], and Dalle et al. [25] that patients were
ligible for UCBT if fully matched siblings or fully
atched unrelated BM donors were not available im-
ediately or within a satisfactory time frame (in the
ase of Barker et al. [26], within 3 months of search
nitiation). In Dalle et al. [25], this intention-to-treat
nalysis is reasonably well laid out; of 91 patients who
nitiated a search, 85 completed a 3-month search
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Figure 7. Srocess, and 84 found suitable grafts. A total of 64 went on to undergo transplantation after 20 cancelled
heir transplantations for various reasons. Of these 64
atients, 37 had a suitable BM donor, although 9 of
hese had CB grafts because of more rapid availability,
eaving 28 who went on to receive a BM transplant.
ine patients who had an urgent need for transplan-
ation, as well as 27 who had not suitable BM donors,
ll received CB transplants.
In the 3 adult studies, recipients of CB weighed
ess, were more likely to have advanced leukemia at
he time of transplantation, and received grafts with
ower cell doses and greater HLA disparities than
atients who received BM transplants. TRM, DFS,
nd OS were dramatically better in CB recipients in
akahashi et al. [27]. This may be explained by a
igniﬁcantly shorter donor search to transplantation
imes in CB recipients (median, 2.8 months; range,
.7–36.3 months vs median, 10.8 months; range, 4.4–
2.1 months; P  .01). Donor search to transplanta-
ion time was not reported in the other 2 studies.
here may also be relevance in the fact that CB
ecipients tended to be older than BM recipients in
akahashi et al. [27], in contrast to the other 2 studies,
n which the converse was true. Finally, differences in
atient ethnicity may be signiﬁcant.
All 3 pediatric studies demonstrated signiﬁcantly
lower neutrophil and platelet engraftment in CB re-
ipients, with the exception of Barker et al. [26], in
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W. H. Y. Khee et al.452f the BM recipients. No signiﬁcant difference in
elapse rate and OS between CB and BM recipients
as found in these studies. Regarding acute and
hronic GVHD development, Rocha et al. [24] re-
orted lower risk in the CB group, in contrast with the
ther 2 studies, which reported similar risk. It is note-
orthy, however, that 20% of unmanipulated BM
ecipients in this study received HLA-mismatched
rafts. Mismatched BMTs have been associated with a
ery high risk of GVHD in pediatric recipients [30].
evertheless, all 3 studies did not ﬁnd an increased
isk of acute (aGVHD) or chronic GVHD (cGVHD)
evelopment despite markedly greater HLA disparity
n CB transplants compared with BM transplants.
The comparison here is between UCBT and
BMT; peripheral blood stem cell transplantation
PBSCT) is not included in the analysis. In PBSCT,
ematopoietic engraftment is generally faster, but
VHD (especially cGVHD) is somewhat more se-
ere. However, numerous comparisons have found no
ifferences in survival between UBMT and unrelated
onor PBSCT (UPBSCT) except in patients in a late
isease stage, in whom UPBSCT appears to be better
31,32]. Thus, although UCBT would be expected to
ave even more pronounced difference in engraftment
nd GVHD compared with UPBSCT, survival out-
omes are likely to be similar, although any variance
n outcomes of patients in late disease stage will be
nteresting to study. Finally, it is important to note
hat the patients in our meta-analysis all underwent
yeloablative preparative regimens for their trans-
lantation. Reduced-intensity conditioning regi-
ens [33,34] would probably reduce the dependency
n engraftment for survival, although any differences
n a graft-versus-tumor effect probably would be more
bvious in that setting. Interestingly, a study on pa-
ients with advanced Hodgkin’s lymphoma found
omparable results between UBMT and HLA-
atched sibling donor HSCT after a reduced-inten-
ity preparative regimen [35].
This meta-analysis was performed using aggregate
atient data (APD) as opposed to individual patient
ata (IPD) [36-38]. Whereas IPD is most suitable for
ime-to-event or survival data because of its ability to
pdate data, provide longer follow-up, and study the
mpact of individual patient characteristics, it is not
lways possible. This is especially true when time or
esources are limited and when the original study data
re not available or are available from only a biased
ample of studies. We performed this meta-analysis
ased on APD because of limitations in sourcing orig-
nal study data from all sources.
Because of the unavailability of randomized and
ontrolled clinical trials, we performed pooled analysis
f retrospective comparative studies and conﬁrmed
hat UCBT in children and adults had equivalent
utcomes compared with UBMT despite the greateronor–recipient HLA disparity with UCBT. Conse-
uently, for patients without a BM donor who is
ptimally matched and readily available (especially in
ases of urgent need for transplantation), and even for
atients with potential unrelated donors, 1 or 2 anti-
en-mismatched UCBT is a viable, equally effective
lternative for patients needing matched donor
BMT.
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